Compare Ascendis Pharma A/S (ASND) vs Raytheon Technologies Corp (RTX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Raytheon Technologies Corp — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Raytheon Technologies Corp trades at $195.88 (market cap $263.86B). The key difference: Raytheon Technologies Corp is far larger — about 14.9× Ascendis Pharma A/S's market cap, and Raytheon Technologies Corp pays a 1.49% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | RTX | |
|---|---|---|
Market Cap | $17.74B | $263.86B |
Sector | Health | Industrials |
52-Week High | $277.18 | $212.16 |
52-Week Low | $163.32 | $146.87 |
Enterprise Value | $18.11B | $295.97B |
Dividend Yield | — | 1.49% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
RTX trades at $195.93, up 0.37% today, with a bullish technical signal and strong analyst support. Recent earnings beats, including Q1 2026 EPS of $1.78 versus $1.51 expected, highlight robust operational performance. Revenue grew to $88.60 billion in 2025, with net income margin improving to 8.03%. The company secured a $515 million U.S. Navy contract for SPY-6 radars (PRNewsWire, 2026-06-03), reinforcing its defense segment strength.
The outlook is positive, driven by defense contract wins and commercial aerospace recovery, but risks include debt levels and geopolitical uncertainties. With a consensus price target of $213.00 (18 buy, 8 hold, 0 sell), the stock offers potential upside, though valuation multiples like a P/E of 36.76 warrant monitoring amid interest rate sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Raytheon Technologies Corp
Raytheon Technologies is a diversified aerospace and defense industrial company formed from the merger of United Technologies and Raytheon, with roughly equal exposure as a supplier to commercial aerospace manufactures and to the defense market as a prime and subprime contractor.
Read more on RTX →
